RxDoctor Payments Data

Nirmal Shah, DO

Anesthesiology · Allentown, PANPI 1770966707

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $55,670 of the $84,976 with a category attached, or 65.5%. Medtronic accounts for 80.0% of it on its own, with 40 other manufacturers making up the rest. Among anesthesiology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,976in general payments, 2019–2025

Across 712 payments — averaging $119.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$68K
  • Boston Scientific$4K
  • Nevro Corp.$2K
  • Genesys Orthopedics Systems, L.L.C.$2K
  • Abbott$1K
  • Painteq LLC$1K
  • plus $6K from 35 others

What the payments were for

  • Speaking & faculty fees$55,67066%
  • Travel & lodging$8,58410%
  • Food & beverage$19,92923%
  • Education$7791%
  • Gifts$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,976 in reported general payments places this provider in the 95th percentile of 2,015 anesthesiology providers in Pennsylvania.

See all anesthesiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$225,811
Medicare patients
476
Services billed
2,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl62$48,288
Buprenorphine90$23,029
Gabapentin288$4,832
Pregabalin165$3,924
Lidocaine57$3,908
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen218$3,848
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen83$1,505
Celecoxib68$1,383
Tizanidine Hcl139$1,242
Baclofen67$1,221
Methocarbamol95$1,139
Oxycodone Hcl58$918
Tramadol Hcl110$755
Cyclobenzaprine Hcl62$701
Orphenadrine Citrate ErOrphenadrine Citrate22$636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$752$48,28862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,015 anesthesiology providers in Pennsylvania.

Other anesthesiology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →